Ian Mortimer serves as President and Chief Executive Officer of Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for epilepsy and other neurological disorders. With over two decades of experience in the pharmaceutical industry, Mortimer joined Xenon in 2004 as Vice President of Clinical Development. Prior to Xenon, he held senior roles at MDS Pharma Services, where he was Director of Clinical Operations, and at Quintiles Transnational, building expertise in clinical trial management, regulatory affairs, and drug development strategies. Under Mortimer's leadership, Xenon has achieved significant milestones, including its initial public offering on the NASDAQ in 2014 and the advancement of its lead candidate, XEN1101, a potassium channel modulator, into Phase 3 clinical trials for focal epilepsy following promising Phase 2b results. He has overseen strategic partnerships, such as collaborations with Neurocrine Biosciences, and secured substantial financing to fuel the company's pipeline. Mortimer's strategic vision has positioned Xenon as a leader in precision neurology, emphasizing patient-centric innovation and operational excellence. As CEO, Mortimer drives Xenon's mission to address unmet needs in neurological diseases, fostering a culture of scientific rigor and cross-functional collaboration. His tenure has been marked by robust growth, with the company expanding its team and research capabilities while maintaining a focus on delivering transformative treatments to patients worldwide.